Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...

MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

10-year deal that Gilead struck with Arcus in 2020, paying $175 million upfront for rights to the PD-1 checkpoint inhibitor zimberelimab plus options on the rest of Arcus’ pipeline. Gilead took ...

Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas are part of the Zacks top Analyst Blog ...

Next, the earnings call focused on coming catalysts from Gilead's pipeline. Lenacapavir for HIV prevention was designated by Science magazine as breakthrough of the year for 2024. Following FDA ...

Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – ...

Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...